{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:11:04Z","timestamp":1793045464285,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170596"],"award-info":[{"award-number":["82170596"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFC2600200"],"award-info":[{"award-number":["2021YFC2600200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.heliyon.2024.e28653","type":"journal-article","created":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T05:36:19Z","timestamp":1711172179000},"page":"e28653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The efficacy of antiviral treatment in chronic hepatitis B patients with hepatic steatosis"],"prefix":"10.1016","volume":"10","author":[{"given":"Danqing","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4052-5157","authenticated-orcid":false,"given":"Hongwu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e28653_bib1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"7","author":"Collaborators","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.heliyon.2024.e28653_bib2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2471\/BLT.18.219469","article-title":"Countdown to 2030: eliminating hepatitis B disease, China","volume":"97","author":"Liu","year":"2019","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.heliyon.2024.e28653_bib3","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/liv.13253","article-title":"Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients","volume":"36","author":"Su","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.heliyon.2024.e28653_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cgh.2019.07.010","article-title":"Outcomes of long-term treatment of chronic HBV infection with entecavir or other Agents from a randomized trial in 24 countries","volume":"18","author":"Hou","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e28653_bib5","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.14309\/ajg.0000000000001195","article-title":"Antiviral therapy reduces risk of cirrhosis in noncirrhotic HBV patients among 4 urban safety-net health systems","volume":"116","author":"Wong","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.heliyon.2024.e28653_bib6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.heliyon.2024.e28653_bib7","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1111\/liv.15252","article-title":"Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia","volume":"42","author":"Yang","year":"2022","journal-title":"Liver Int."},{"key":"10.1016\/j.heliyon.2024.e28653_bib8","first-page":"20","article-title":"High incidence of hepatitis B core antibody positivity in metabolic-associated fatty liver disease-related cirrhosis","volume":"2","author":"Ergenc","year":"2021","journal-title":"Hepatol Forum"},{"key":"10.1016\/j.heliyon.2024.e28653_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jhepr.2019.02.002","article-title":"Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load","volume":"1","author":"Peleg","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.heliyon.2024.e28653_bib11","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","article-title":"Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B","volume":"73","author":"Mak","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e28653_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/hep.30857","article-title":"Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B","volume":"71","author":"Choi","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e28653_bib12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address eee, European association for the study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e28653_bib13","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e28653_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.heliyon.2024.e28653_bib15","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/apt.14577","article-title":"An expert consensus for the management of chronic hepatitis B in Asian Americans","volume":"47","author":"Tong","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2024.e28653_bib16","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/apt.16097","article-title":"East Asia expert opinion on treatment initiation for chronic hepatitis B","volume":"52","author":"Kao","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2024.e28653_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms8101526","article-title":"A new endemic of concomitant nonalcoholic fatty liver disease and chronic hepatitis B","volume":"8","author":"Hanif","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.heliyon.2024.e28653_bib18","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e28653_bib19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"Asociacion Latinoamericana para el Estudio del H. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e28653_bib20","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2024.e28653_bib21","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2024.e28653_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2893.2008.01037.x","article-title":"Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B","volume":"16","author":"Chan","year":"2009","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.heliyon.2024.e28653_bib23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/hep.32716","article-title":"Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes","volume":"77","author":"Mak","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e28653_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/jvh.12766","article-title":"Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study","volume":"25","author":"Hui","year":"2018","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.heliyon.2024.e28653_bib25","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cgh.2017.09.044","article-title":"Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B","volume":"16","author":"Seto","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e28653_bib26","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/liv.14415","article-title":"Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients","volume":"40","author":"Li","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.heliyon.2024.e28653_bib27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2024.e28653_bib28","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/sj.ijo.0803479","article-title":"Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?","volume":"31","author":"Chu","year":"2007","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.heliyon.2024.e28653_bib29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10620-012-2343-9","article-title":"Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without","volume":"58","author":"Chu","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.heliyon.2024.e28653_bib30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/liv.14369","article-title":"Chronic hepatitis B and non-alcoholic fatty liver disease: conspirators or competitors?","volume":"40","author":"Zhang","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.heliyon.2024.e28653_bib31","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cld.2017.03.004","article-title":"Metabolic manifestations of hepatitis C virus: diabetes mellitus","volume":"21","author":"Serfaty","year":"2017","journal-title":"Dyslipidemia. Clin Liver Dis"},{"key":"10.1016\/j.heliyon.2024.e28653_bib32","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1053\/j.gastro.2003.11.020","article-title":"Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease","volume":"126","author":"Lonardo","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2024.e28653_bib33","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1128\/JVI.02604-15","article-title":"Hepatitis B virus X protein induces hepatic steatosis by enhancing the expression of liver fatty acid binding protein","volume":"90","author":"Wu","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e28653_bib34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/apt.15575","article-title":"Systematic review: chronic viral hepatitis and metabolic derangement","volume":"51","author":"Wang","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2024.e28653_bib35","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12072-018-9877-7","article-title":"Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model","volume":"12","author":"Hu","year":"2018","journal-title":"Hepatol Int"},{"key":"10.1016\/j.heliyon.2024.e28653_bib36","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3350\/cmh.2021.0314","article-title":"Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: a propensity score-matched analysis","volume":"28","author":"Jeong","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e28653_bib37","doi-asserted-by":"crossref","first-page":"964","DOI":"10.4254\/wjh.v15.i8.964","article-title":"Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients","volume":"15","author":"Lai","year":"2023","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e28653_bib38","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/apt.17765","article-title":"Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B","volume":"59","author":"Cheng","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2024.e28653_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhep.2008.10.014","article-title":"Liver biopsy: the best, not the gold standard","volume":"50","author":"Bedossa","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e28653_bib40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2009.05.023","article-title":"Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance","volume":"51","author":"Schwenzer","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e28653_bib41","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2013.12.018","article-title":"Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations","volume":"60","author":"de Ledinghen","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e28653_bib42","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/liv.12282","article-title":"Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population","volume":"34","author":"Chon","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.heliyon.2024.e28653_bib43","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/apt.13804","article-title":"Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B","volume":"44","author":"Seto","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2024.e28653_bib44","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1053\/j.gastro.2017.03.017","article-title":"American gastroenterological association Institute guideline on the role of elastography in the evaluation of liver fibrosis","volume":"152","author":"Lim","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2024.e28653_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2012.09.025","article-title":"Association between anthropometric parameters and measurements of liver stiffness by transient elastography","volume":"11","author":"Wong","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e28653_bib46","article-title":"Application of fatty liver inhibition of progression algorithm and steatosis, activity, and fibrosis score to assess the impact of non-alcoholic fatty liver on untreated chronic hepatitis B patients","volume":"11","author":"Huang","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402404684X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402404684X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:19:28Z","timestamp":1784207968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402404684X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S240584402404684X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28653","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of antiviral treatment in chronic hepatitis B patients with hepatic steatosis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e28653"}}